HRG-β3 inhibitors are a class of compounds designed to specifically target and inhibit the activity of HRG-β3, a member of the heregulin family of proteins. HRG-β3 (heregulin-β3) is one of several isoforms of the heregulin protein family that plays a crucial role in various cellular signaling pathways. These inhibitors work by binding to HRG-β3 and preventing its interaction with receptors such as ErbB3 and ErbB4, which are part of the ErbB receptor family. By interfering with HRG-β3's ability to engage with its target receptors, the inhibitors modulate the downstream signaling cascades that are typically triggered by HRG-β3's activity, affecting cellular processes such as growth, differentiation, and intracellular communication.
HRG-β3 inhibitors can vary widely depending on their chemical makeup, but they generally possess moieties that enable selective binding to HRG-β3. These compounds are often designed with high specificity for HRG-β3 to minimize off-target effects on other proteins. The design of HRG-β3 inhibitors is guided by structural biology, which allows for precise interactions at the molecular level, ensuring that the binding affinity is strong enough to effectively block HRG-β3 function. HRG-β3 inhibitors may be synthesized using organic chemistry techniques or discovered through high-throughput screening of chemical libraries. Their development involves fine-tuning molecular features such as hydrophobicity, charge distribution, and molecular size to optimize their performance in biochemical environments.
| 製品名 | CAS # | カタログ # | 数量 | 価格 | 引用文献 | レーティング |
|---|---|---|---|---|---|---|
Telmisartan | 144701-48-4 | sc-204907 sc-204907A | 50 mg 100 mg | $71.00 $92.00 | 8 | |
アンジオテンシンII受容体拮抗薬は、血管機能と関連するシグナル伝達経路に影響を与える可能性がある。 | ||||||
Losartan | 114798-26-4 | sc-353662 | 100 mg | $127.00 | 18 | |
もう一つのアンジオテンシンII受容体拮抗薬で、血圧と血管新生に影響を及ぼす可能性がある。 | ||||||
Atorvastatin | 134523-00-5 | sc-337542A sc-337542 | 50 mg 100 mg | $252.00 $495.00 | 9 | |
HMG-CoA還元酵素を阻害し、コレステロールレベルや炎症や血管新生に関連する細胞シグナル伝達に影響を及ぼす可能性がある。 | ||||||
BIBF1120 | 656247-17-5 | sc-364433 sc-364433A | 5 mg 10 mg | $180.00 $315.00 | 2 | |
血管新生に関与する複数のチロシンキナーゼを阻害し、HRG-β3が関与する過程に影響を及ぼす可能性がある。 | ||||||
Thalidomide | 50-35-1 | sc-201445 sc-201445A | 100 mg 500 mg | $109.00 $350.00 | 8 | |
免疫応答を調節し、血管新生を阻害し、HRG-β3関連経路に影響を与える可能性がある。 | ||||||
Sorafenib | 284461-73-0 | sc-220125 sc-220125A sc-220125B | 5 mg 50 mg 500 mg | $56.00 $260.00 $416.00 | 129 | |
RAFキナーゼと他の受容体を阻害し、細胞増殖と血管新生に影響を与える可能性がある。 | ||||||
Metformin | 657-24-9 | sc-507370 | 10 mg | $77.00 | 2 | |
AMPKを活性化し、HRG-β3に関連する代謝経路や細胞増殖に影響を及ぼす可能性がある。 | ||||||
Ibrutinib | 936563-96-1 | sc-483194 | 10 mg | $153.00 | 5 | |
ブルトン型チロシンキナーゼを阻害し、B細胞のシグナル伝達と免疫応答に影響を及ぼす可能性がある。 | ||||||